Table 2.
Male (n = 144) | Female (n = 39) | |
---|---|---|
Protease inhibitor-based HAART | 69% (n = 100) | 77% (n = 30) |
Ritonavir | 70% | 47% |
High-dose ritonavir | 39% | 30% |
Saquinavir | 41% | 40% |
Indinavir | 14% | 20% |
Nelfinavir | 17% | 23% |
Kaletra | 23% | 7% |
Atazanavir | 0% | 10% |
NNRTI-based HAART | 22% (n = 31) | 18% (n = 7) |
Efavirenz | 77% | 71% |
Nucleoside-sparing | 10% | 0% |
Abbreviations: HAART, highly-active antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitors.